Gemigliptin

Generic Name
Gemigliptin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C18H19F8N5O2
CAS Number
911637-19-9
Unique Ingredient Identifier
5DHU18M5D6
Background

Gemigliptin is under investigation in Type 2 Diabetes Mellitus. Gemigliptin has been investigated for the treatment of Cancer and Cisplatin Adverse Reaction.

Associated Conditions
Type 2 Diabetes Mellitus
Associated Therapies
-

Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes

Phase 4
Recruiting
Conditions
Interventions
First Posted Date
2022-12-23
Last Posted Date
2023-03-08
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
80
Registration Number
NCT05663736
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of

Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes

First Posted Date
2022-01-18
Last Posted Date
2023-08-01
Lead Sponsor
Wonju Severance Christian Hospital
Target Recruit Count
122
Registration Number
NCT05194592
Locations
🇰🇷

Yonsei University Wonju College of Medicine, Wonju, Gangwondo, Korea, Republic of

Gemigliptin and Biomarkers of Kidney Injury and Vascular Calcification

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2021-01-12
Last Posted Date
2021-01-14
Lead Sponsor
Bangkok Metropolitan Administration Medical College and Vajira Hospital
Target Recruit Count
201
Registration Number
NCT04705506
Locations
🇹🇭

Faculty of Medicine ,Vajira Hospital, Bangkok, Thailand

🇹🇭

Department of Medicine,Police General Hospital,Thailand, Bangkok, Thailand

🇹🇭

2 Division of Nephrology,Department of Medicine Pramongkutklao Hospital and College of Medicine,Thailand, Bangkok, Thailand

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

First Posted Date
2018-06-21
Last Posted Date
2018-06-21
Lead Sponsor
LG Chem
Target Recruit Count
48
Registration Number
NCT03565458
Locations
🇰🇷

LG chem, Seoul, Gangseo-Gu, Korea, Republic of

An Assessment of Pharmacokinetic Gemigliptin and Metformin Interactions in Healthy Mexican Volunteers

First Posted Date
2017-10-16
Last Posted Date
2017-10-16
Lead Sponsor
Stendhal Americas, S.A.
Target Recruit Count
34
Registration Number
NCT03310749
Locations
🇲🇽

Unidad de Farmacología Clínica de la Facultad de Medicina de la Universidad Nacional Autónoma de México, Nezahualcóyotl, Estado de México, Mexico

Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients

First Posted Date
2015-07-16
Last Posted Date
2015-07-16
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
54
Registration Number
NCT02500329
Locations
🇰🇷

Boramae medical center, Seoul, Korea, Republic of

An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin

Completed
Conditions
Interventions
First Posted Date
2014-11-14
Last Posted Date
2019-01-24
Lead Sponsor
LG Life Sciences
Target Recruit Count
5180
Registration Number
NCT02290301
Locations
🇰🇷

Pusan National University Hospital, Busan, Korea, Republic of

Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury

First Posted Date
2014-09-26
Last Posted Date
2016-04-20
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
182
Registration Number
NCT02250872
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2014-07-10
Last Posted Date
2016-04-21
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
10
Registration Number
NCT02186080
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath